| ID | 1002 |
| Name of the vaccine | BCG AJV |
| Microbe | Bacteria |
| Disease name | Pulmonary Tuberculosis (TB) |
| Name of bacteria | Mycobacterium tuberculosis |
| Type of vaccine | Live attenuated |
| Nucleic acid content | DNA |
| Age | Children at higher risk. |
| Description of the vaccine | BCG (Bacillus Calmette-Guerin) Danish strain 1331. |
| Name of the manufacturer | AJ Vaccines |
| Name of the manufacturing country | Denmark |
| Year of manufacture | 1953 |
| Clinical Phase status | Approved |
| Bacterial strain | Acid-fast Gram-positive bacteria. |
| Efficacy | 70-80% effective in children. |
| Vaccine formulation | Powder and solvent for suspension |
| Dosage | Infants under 12 months : 0.05 mL and children 12 months and older, adults: 0.1 mL |
| Mechanism of action | Cell-mediated immune response. |
| Route of administration | Intradermal |
| Indications | Give as soon as possible after birth to prevent increased risk of TB. |
| Export | Marketing authorisation holder - AJ Vaccines A/S |
| Approval | UK MHRA and EMA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Hardness at the injection site. |
| Post vaccination | No immunisation should be given in the same arm for at least three months. |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://vk.ovg.ox.ac.uk/vk/bcg-vaccine |
| Other name | NA |
| Additional Links | https://www.medicines.org.uk/emc/product/9890#gref
|